

INDEX

- Acetaminophen, 245
N-Acetylcysteine, 269
Acinic cell carcinoma, 76
Ad-p53, 294-295
Addictions, assessment of, 223.
 See also Smoking
Adenocarcinoma
 atypical adenomatous
 hyperplasia progression to,
 67
 chest radiography of, 11-12
 CNS metastases, 28
 immunohistochemistry, 76-77
 k-ras mutations, 15
 mesotheliomas distinguished
 from, 77
 NSCLC classification as, 60
 p53 mutations, 78
 pathology, 73-74
 radiographic evaluations, 31
 WHO classification, 63
Adenoid cystic carcinoma, 76, 227
Adenoma, 47, 63
Adenosquamous carcinoma, 64,
 74
Adrenal glands, 6, 27, 30, 46
Adrenocorticotrophic hormone, 29
Age
 cancer mortality rates, 4
 chemotherapy and, 162
 comorbid conditions and, 161
 lung cancer frequency, 7
 SCLC outcomes and, 188
Air leaks, prevention, 251-252
Air pollution, 6, 282
Airway compression, 228,
 235-236
Albumin levels, 29
Alcohol intake, 246
Alkaline phosphatase, 28, 46, 188,
 209
Alkylating agents, 210. *See also*
 entries for specific agents
Alpha-tocopherol. *See*
 α -Tocopherol
Altered mental status, 27, 29
Aluminum hydroxide, 245
Alveolar epithelial hyperplasia.
 See Atypical adenomatous
 hyperplasia
American Cancer Society (ACS),
 37
American College of Radiology
 Imaging Network Trial, 38
American College of Surgeons,
 107
American Joint Committee on
 Cancer (AJCC), 8, 102
American Society of Clinical
 Oncology (ASCO), 163-164
Amifostine, 21
Amputations, 225
Androgen receptor gene, 66
Anemia, 201, 250, 253
Anesthesiology, 92-93, 225
Angiogenesis, 287, 296
Anorexia, 7, 28, 223. *See also*
 Appetite; Cachexia;
 Weight loss
Anterior pituitary, 76-77

- Anterior spinal column
reconstruction, 226
- Anthracois, 30
- Anthracycline analogues, 210. *See also entries for specific analogues*
- Anti-Lung Cancer Association, 276
- Antibiotics, 201, 254
- Antibody therapy, 178-179
- Antifungals, 245
- Aortic lymph nodes, 124
- Aortopulmonary window lymph nodes, 124, 125
- Apoptosis, 287
- Appetite, 246. *See also Anorexia; Cachexia; Weight loss*
- Arachidonic acid, 265, 266
- Arm exercises, 91
- Arterial blood gas analysis, 32, 122-123
- Asbestos, 6
- Aspartate aminotransferase, 46
- ATBC Cancer Prevention Study Group, 268
- Atelectasis, 14, 27
- Atypical adenomatous hyperplasia (AAH), 62, 63, 66-67
- Atypical alveolar cuboidal cell hyperplasia.
See Atypical adenomatous hyperplasia
- Atypical alveolar hyperplasia. *See Atypical adenomatous hyperplasia*
- Atypical carcinoid tumors, 70-71, 71-72, 78
- Azacitidine analogues, 296
- B72.3, 77
- Basal cell hyperplasia, 283
- Basaloid carcinoma, 74
- Base-of-skull metastases, 199
- Bcl-2* gene, 78, 286, 287
- Ber-EP4, 77
- Best supportive care (BSC)
advanced NSCLC, 159-160, 161
docetaxel and, 165
gemcitabine and, 165
paclitaxel and, 165
SCLC, 210
vinorelbine and, 162, 165
- Beta-carotene. *See β-Carotene*
- Bimodality Lung Oncology Team (BLOT), 109-110
- Biologicals, chemotherapy, 178-179
- Biopsies
bone marrow, 112
mediastinal lymph nodes, 12
preoperative evaluation, 60-61
transbronchial technique, 13, 33, 60
transthoracic needle aspiration (TTNA), 13-14, 34, 42-43
- Bleomycin, 201, 229
- Blood cell counts, 29
- Blood loss, 143, 251
- Blood supply, 6
- Bone metastases
coronal whole-body PET, 49-50
frequency of, 6, 27
imaging for detection of, 31, 46, 48-50
management of related pain, 28, 225
- Bone marrow, 28, 112, 188
- Bone scans
NSCLC, 48, 104
practice guidelines, 87-88
pretreatment evaluation, 14
SCLC, 188
- Borg scale, 230
- Brachial plexus, 86-87, 225
- Brachytherapy, 154-155, 237
- Brain
metastases, 6, 46, 104, 224
parenchyma, 199

- pretreatment imaging
 - evaluation, 14, 31, 87-88
- prophylactic irradiation, 135, 188
- surgery, 19
- Breast cancer, 5, 178
- Bronchial arteries, 6
- Bronchial brushing, 60-61
- Bronchial epithelial metaplasia, 262
- Bronchial sleeve resection, 227
- Bronchial stump dehiscence, 252-253
- Bronchial washings, 60-61
- Bronchioalveolar
 - adenocarcinoma (BAC), 74
- Bronchiolization of the alveolar septae, 66
- Bronchioloalveolar adenoma. *See* Atypical adenomatous hyperplasia
- Bronchodilators, 87
- Bronchogenic carcinomas, 68
- Bronchoplasty, 132-133, 227
- Bronchopleural fistula, 252
- Bronchoscopy
 - extrinsic compression of
 - airway, 235-236
 - fiber-optic, 7
 - flexible fiber-optic, 33-34
 - fluorescence, 13
 - intraluminal tumors, 236-237
 - mediastinal lymph nodes, 14
 - pretreatment evaluation, 14
- Bronchus, obstruction of, 153
- C225 (cetuximab), 274, 293
- Cachexia, 28, 237-238. *See also* Anorexia; Appetite; Weight loss
- Calcification, 38-40
- Calretinin, 77
- Carbon dioxide. *See* Diffusing capacity
- Carbon monoxide. *See* Diffusing capacity
- Carbonated beverages, 246
- Carboplatin
 - NSCLC, 18, 161
 - paclitaxel and, 163
 - preoperative, 109-110
 - second-generation agents and, 170-173
 - third-generation agents and, 167, 170-173
- Carcinoembryonic antigen, 29, 66, 77
- Carcinogen exposure, 283
- Carcinogenesis, models of, 258-259
- Carcinoid tumor, 64, 70-71, 71-72, 78
- Carcinoma
 - acinic cell, 76
 - adenoid cystic, 76, 227
 - adenosquamous, 64, 74
 - basaloid, 74
 - bronchioalveolar
 - adenocarcinoma, 74
 - bronchogenic, 68
 - epimyoepithelial, 76
 - head and neck squamous cell, 263, 272, 274
 - in situ, 62, 63, 65, 78, 283
 - large cell. *See* Large cell carcinoma
 - mucoepidermoid, 76
 - nonmucinous bronchioalveolar
 - adenocarcinoma, 66-67
 - pleomorphic, 75
 - with pleomorphic, sarcomatoid, or sarcomatous elements, 64, 75-76
 - salivary-gland type, 64, 76
 - sarcomatoid, 75, 78
 - segmental, 124, 126
 - with spindle and/or giant cells, 75
 - squamous cell. *See* Squamous cell carcinoma
 - unclassified, 64
- Carcinosarcoma, 75

- Cardiac murmurs, 104
- Cardiomyopathy, 248
- Cardiovascular screening, 122
- Carina, invasion of, 135, 136
- Carofate (sucralfate) slurries, 245
- β -Carotene, 264, 268
- β -Carotene and Retinol Efficacy Trial (CARET), 268
- Carotenoids, 262
- Carotid bruits, 104
- Catechins, 267
- Catheter
- chronic indwelling pleural, 20, 230-236
 - epidural, 91, 93
- Celecoxib (Celebrex), 267, 296
- Cell cycle, 285-286, 296
- Cellulitis, 254
- Central nervous system (CNS).
- See also* Brain; Spinal cord
 - metastases, 27-28, 46, 198-200
 - radiographic evaluation, 31
- Centromere-binding proteins, 293
- Cervical mediastinoscopy, 12
- Cetuximab (C225), 274, 293
- Chamberlain procedure, 12
- Chemical shift analysis, 46, 47
- Chemoprevention, 260-275, 290
- Chemoradiation therapy
- limited-stage SCLC, 190-201
 - NSCLC, 20-22, 120, 148-152
 - preoperative, 244
 - RTOG 91-06 trial, 149, 150
 - RTOG 92-04 trial, 150
 - RTOG 93-09 trial, 131-132
 - RTOG 94-10 trial, 151-152
 - side effects of, 247
 - T4N0-1 tumors, 135
- Chemotherapy. *See also entries for specific drugs*
- agent selection, 164-178
 - alternating regimens, 214-215
 - assessment of patients after, 36
 - biologicals, 178-179
 - combination, 20
 - dosages in limited-stage SCLC, 194
 - dose intensification, 215
 - downstaging with, 136
 - neoadjuvant, 19, 109-110, 243-244
 - NSCLC, 18, 105, 108-110, 120, 158-185
 - older patients and, 162
 - postoperative, 244
 - practice guidelines, 87-88
 - radiation therapy and. *See* Chemoradiation therapy
 - refractory or recurrent disease, 215-217
 - SCLC, 189-201, 207-219
 - timing and duration, 163-164
 - T3N1 Pancoast tumors, 130
- Chest pain, 7, 26, 27, 209
- Chest tube drainage, 91
- Chest wall
- en bloc resection, 226
 - invasion of, 6, 43, 44
 - pain at diagnosis, 7
 - radiographic evaluations, 31
 - resection, 128
- Chondrosarcoma, 75
- Chromium, 6
- Chromogranin stain, 71, 72, 77
- Chromosomes, 66, 78. *See also* Loss of heterozygosity
- Chronic indwelling pleural catheter, 20, 230-236
- Chronic obstructive pulmonary disease, 228
- Cigarette smoking. *See* Smoking
- 13-*cis*-Retinoic acid, 262, 269-270
- Cisplatin
- combination therapy, 21
 - etoposide and, 166
 - gemcitabine and, 166, 168
 - irinotecan and, 166

- with mitomycin and vinblastine (MVP therapy), 163
- NSCLC and, 148
- paclitaxel and, 168
- practice guidelines, 89
- RTOG 91-06, 149
- RTOG 92-04, 150
- RTOG 94-10, 151-152
- SCLC and, 191, 193, 194, 195
- second-generation agents with, 170-173
- third-generation agents and, 167, 170-173
- tirapazamine and, 168
- vindesine and, 166
- vinorelbine and, 166, 168
- Clara cells, 76-77
- Classification, lung tumors, 62-76
- Clear cell carcinomas, 74
- Clinical pathways, 81-100
 - cost analysis, 94-96
 - deviations from, 96-97
 - future trends, 97-99
 - patient educational materials, 90, 91
 - pulmonary resection, 89-97
- Clinical practice guidelines, 81-100, 163-164, 213
- Clinical target volume (CTV), 144-145
- Clonogens, prevention of, 190
- Colorectal cancer, 5
- Communication
 - conferences, 16
 - guideline development, 83-86
 - multidisciplinary team approach, 16
 - pathway design, 89-97
 - presurgical assessments, 250
- Comorbid conditions, 29, 161
- Computed tomography (CT)
 - abdomen, 30
 - adrenal metastases, 27
 - chest, 30
 - contrast materials, 40
 - densitometry, 39
 - estimation of growth, 39-40
 - evaluation of response to treatment, 51
 - extrinsic compression of airway, 235-236
 - false positives, 30
 - helical, 37, 276-277
 - low-resolution, 7
 - NSCLC, 104
 - pretreatment evaluation, 12, 14
 - SCLC workup, 188
 - TTNA biopsy, 42-43
- Constipation, 29, 246, 253
- Constitutional symptoms, 28-29.
 - See also entries for specific symptoms*
- Continuity of care. *See* Follow-up care; Multidisciplinary care
- COPE trial, 193-194
- Core needle biopsy, 60
- Cost analysis, 94-96
- Coughs, 26, 27, 209
- Cryotherapy, 237
- Cushing's syndrome, 209-210
- Cyclin D1, 284, 286
- Cyclin E, 284, 286
- Cyclooxygenase inhibitors, 266-267
- Cyclooxygenases, 266-267, 296
- Cyclophosphamide
 - combination therapy, 21
 - SCLC, 191, 193-195, 210
- Cyclophosphamide, doxorubicin, and vincristine (CAV) therapy, 210-211, 214-215, 216
- Cytokeratins, 76, 77, 112
- Cytologic examination, 7
- Data collection, 89-97
- Databases, 89, 91
- Depression, 224, 225
- Dexamethasone, 246

- Diagnosis. *See also under entries for specific cancers*
 algorithm, 58-62
 imaging techniques, 38-43
 symptoms at time of, 7-8
- Diaphragm, 6
- Dietary modification, 248
- Dietary supplements, 246
- Dieticians, 246
- Differentiation, 59
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), 62, 63, 68
- Diffusing capacity, 32, 105, 228
- Diphenhydramine, 245
- Discharge, clinical pathways and, 93
- Distant metastasis. *See* Metastatic disease
- DNA damage, 282
- Docetaxel
 best supportive care and, 165
 platinum-based agents with, 161, 170
 quality of life and, 164
 SCLC and, 210, 216
 second-line therapy with, 174
- Downstaging, 136
- Doxorubicin, SCLC therapy, 191, 193-195, 201, 210
- Doxycycline sclerosis, 230
- Dysphagia, 245
- Dyspnea
 at diagnosis, 7, 26, 27
 extensive-stage SCLC, 209
 lung-sparing surgery, 227
 palliative care, 222, 228
- Early Lung Cancer Action Project, 7, 37-38, 112-113, 276
- Eastern Cooperative Oncology Group (ECOG)
 1594 study, 169, 172
 Intergroup study 0096, 196
 performance scales, 222
 SCLC protocol, 188, 191
- Eaton-Lambert syndrome, 210
- E1B* gene, 272
- Education
 antitobacco policies, 275
 patient materials, 89, 90, 91, 92, 111
- Eicosanoids, 265
- Electrocardiography, 92
- Electrolyte abnormalities, 201, 253
- Electron microscopy, 78
- ELVIS study, 162
- Empyema, 252
- Encapsulation, 59
- End-of-life care, 225
- Endobronchial biopsy, 60-61
- Endobronchial lesions, 60, 153-155
- Endobronchoscopy, 289. *See also* Bronchoscopy
- Endolase antibody, 77
- Endostatin, 296
- Endotracheal lesions, 153-155
- Enteral feeding tubes, 254
- EORTC 8975 study, 172, 175
- Epicatechin, 267
- Epidemiology of lung cancer, 2-3, 4-6, 102, 187, 221
- Epidermal growth factor receptors (EGFR/*erbB-1*), 77, 274-275, 287, 293-294
- Epidural catheters, 91, 93
- Epimyoepithelial carcinoma, 76
- Epipodophyllotoxins, 210
- Epithelial tumors, 59-60, 68
- Erythema, 245
- Erythroplakia, 261
- Erythropoietin, 201, 253
- Esophagitis, 17, 201, 245-246, 247-248
- Esophagus, maximum radiation doses, 249
- Ethylol (WR21-27), 21
- Etiology of lung cancer, 6

- Etoposide
 - cisplatin and, 166
 - platinum-based agents with, 170
 - practice guidelines, 89
 - RTOG 91-06, 149, 150
 - RTOG 92-04, 150
 - RTOG 94-10, 151-152
 - SCLC therapy, 191, 193-195, 210
- Etoposide and carboplatin (EC) therapy, 212, 216
- Etoposide and cisplatin (EP) therapy, 210-211, 214-215, 216
- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), 222
- European Organization for Research and Treatment of Cancer trial, 214
- EUROSCAN study, 269
- Evaluation during therapy, 201
- Exercise testing, 105
- Families, pain management and, 225
- Farnesyl transferase inhibitors (FTIs), 273, 293
- Fat, 39
- Fatigue, 7, 17, 28, 223
- Fentanyl, transdermal, 245-246
- Fever, 7, 26, 27, 28
- FHIT* gene, 285
- Fiber-optic bronchoscopy, 7, 33-34
- Fibrin sealants, 252
- Fibrosis, 51, 52, 246-247
- Field cancerization hypothesis, 258, 283-284
- Fine-needle aspiration, 7, 12, 32, 60-61
- Fissures, tumor extension to, 6
- “Flail” extremities, 225
- Flank pain, 27
- Fluorescence bronchoscopy, 13
- Fluorodeoxyglucose F 18, 36
- Fluorodeoxyglucose positron emission tomography (FDG-PET), 15, 36, 40-42, 45-46, 48
- Fluorouracil, 165
- FocalSeal-L, 252
- Follow-up care, 88, 111, 202. *See also under entries for specific cancers*
- Forced expiratory volumes (FEV₁), 32, 87, 122, 143
- Frozen sections, 61
- 5-FU, 165
- Functional Assessment of Cancer Therapy—Lung, 222
- Gadolinium enhancement, 46
- Gamma-glutamyltranspeptidase, 46
- Gastrin-releasing peptides, 266, 287
- Gastroesophageal reflux, 93, 245
- Gemcitabine
 - advanced NSCLC, 161
 - best supportive care and, 165
 - cisplatin and, 166, 167, 168
 - extensive-stage SCLC, 210
 - platinum-based regimens and, 170, 178
 - quality of life and, 164
 - radiosensitization, 244
 - survival outcomes, 164
 - vinorelbine and, 162
- Gender, survival and, 4, 187, 209
- Gene therapy, 15, 22, 294-295
- Genomic stability, 286
- GEPC 98-02 study, 175, 176
- Glomus sensation, 245
- γ -Glutamyltranspeptidase, 46
- Goldie-Coldman hypothesis, 193
- Gore-Tex, 251
- Granulocyte colony-stimulating factor, 201, 250
- Granulomatous inflammation, 30
- Green tea, 267
- Gross tumor volume (GTV), 144-145

- Growth. *See* Tumor growth
- Guidelines. *See* Clinical practice guidelines
- Guyatt chronic respiratory questionnaire, 230
- H2 blockers, 245
- Head and neck squamous cell carcinoma (HNSCC), 263, 272, 274
- Headaches, 27
- Heart, maximum radiation doses, 249
- Helsinki Accords, 105
- Hematocrit, 46
- Hemoglobin levels, 253
- Hemoptysis, 7, 26, 27, 209, 236
- Hemorrhages, 42-43, 178
- HER-2/*neu* oncogene, 15, 77, 284, 287, 293
- HerceptTest, 77
- Herceptin (trastuzumab), 178
- Hereditary nonpolyposis colon cancer, 286
- High mediastinal lymph nodes, 124, 125
- Hilar lymph nodes
 definition, 126
 image-guided TTNA biopsy, 42-43
 stations, 124
 thoracic radiation therapy, 201
 tumor extension to, 6
 video-assisted thoracoscopy, 12
- Hilum, immobilization, 135, 137
- Histology, 32-34. *See also* Pathology
- History, 10-11, 26-29, 103-105
- Hoarseness, 7, 26
- Hormonal therapy, 225
- Horner's syndrome, 153
- Hospital stay, length of, 93
- Human Genome Project, 286
- Hydration, assessment of, 223
- Hydrocodone, 245
- Hydrocortisone, 245
- Hydrogen peroxide, 245
- Hydrogenated petrolatum, 245
- Hydroxyeicosatetraenoic acids (HETEs), 265-266
- 4-Hydroxyphenylretinamide, 271
- Hypercalcemia, 28, 29
- Hypercapnia, 122
- Hyperfractionated radiation therapy
 RTOG trial 88-08, 149
 RTOG trial 91-06, 150
 thoracic radiation therapy, 195-197
- Hyperglycemia, 29
- Hypokalemia, 29
- Hypomagnesemia, 254
- Hyponatremia, 29
- Hypophosphatemia, 254
- Hypoxia, 122
- Iatrogenic radiation exposure, 6
- Ifosfamide, 163, 170, 177-178, 210
- Imaging techniques, diagnostic, 38-43
- Immunohistochemical staining, 76-77
- Immunohistochemistry, 112
- Immunotherapy, 178-179
- In situ hybridization, 289
- Incentive spirometers, 91
- Infections, 39-40, 42
- Infiltrates, 13
- Inflammation
 FDG-PET false-positives, 42
 hydrocortisone, 245
 PET false-positives, 51
 presurgical assessment, 250
 rate of nodule growth, 39-40
- Informed consent forms, 89
- Institut Gustave-Roussy, 197
- Insulin-like growth factor, 266, 287
- Intensive care units, 93
- Intergroup study 0096, 196
- Interleukin 12, 296

- Interlobar lymph nodes, 124, 126
- International System for Staging
 - Lung Cancer, 8, 9-10, 36
- Intraluminal tumors, 236-237
- Intraoperative evaluations, 61
- Intraparenchymal lymph nodes, 6
- Intrathoracic nodal metastases, 45
- Iressa (ZD1839), 179, 274-275, 293, 296
- Irinotecan
 - cisplatin and, 166
 - platinum-based regimens and, 164, 170, 178
 - SCLC therapy, 210, 216
 - tolerability, 167
- Iron supplementation, 253
- ISIS-3521, 179
- Japanese Clinical Oncology Group, 191, 193, 196-197
- Jaundice, 27
- K-ras* mutations, 66, 78, 259, 273, 284
- K-ras* oncogene, 15-16
- Karnofsky performance status, 222
 - pleural effusion and, 230
 - prognostic significance, 146
 - RTOG 92-04 trial, 149, 150
 - RTOG 94-10 trial, 151-152
- Ki-67, 66, 274, 275
- Kidneys, 6, 46
- Lactate dehydrogenase, 29, 188, 209
- Lactulose syrup, 246
- Laminectomy, 226
- Large cell carcinoma
 - neuroendocrine, 72, 74, 78
 - NSCLC classification as, 60
 - pathology, 74-75
 - with rhabdoid phenotype, 74
 - TTF-1 staining, 76-77
 - WHO classification, 64
- Laryngeal mask airways, 93
- Laser ablation, 237
- Length of hospital stay, 93
- Leptomeninges, 28, 199
- Leucovorin, 165
- Leukopenia, 161, 193
- Leukoplakia, 261, 262-263
- Leukotrienes, 265
- LGD1069 (Targretin), 293
- Lidocaine, 245
- Lipoxygenase inhibitors, 265-266
- Liver, tumor spread to, 6, 27, 46
- Liver function tests, 29
- Lobar lymph nodes, 124, 126
- Lobectomy
 - early-stage NSCLC, 105
 - with en bloc chest wall resection, 226
 - forced expiratory volumes and, 32
 - NSCLC, 17
 - SCLC, 22
 - T1-3N2 tumors, 132-133
- Lomustine, 21
- Loss of heterozygosity (LOH), 66, 285, 289
- Lower paratracheal lymph nodes, 124, 125
- Lung, maximum radiation doses, 249
- Lung Cancer Study Group, 106
- Lung Cancer Symptom Scale, 222
- Lymph nodes, 9, 36, 45-46, 124-126. *See also entries for specific lymph node groups*
- Lymphoepithelioma-like carcinomas, 74
- Magnesium hydroxide, 245
- Magnetic resonance (MR) imaging
 - abdominal, 30
 - adrenal masses, 46, 47
 - evaluation of response to treatment, 51

- Magnetic resonance (MR)
 imaging (*continued*)
 extrinsic compression of
 airways, 235-236
 NSCLC workup, 104
 pretreatment evaluation, 14
 SCLC workup, 188
- Malaise, 7, 223
- Malignant mixed tumors, 76
- Malignant tumors, pathology,
 68-76
- Margins, surgical, 39
- Marimastat, 296
- Maximum voluntary ventilation,
 32
- M. D. Anderson clinical practice
 guidelines, 81-100
- Measurement bias, 111-113
- Mediastinal lymph nodes
 biopsy techniques, 12
 chest radiography, 30
 confirming invasion of, 43, 44
 evaluation, 12
 high, 124, 125
 image-guided TTNA biopsy,
 42-43
 pretreatment CT, 12
 stations, 124
 T1-3N2 tumors, 133
 transbronchial biopsy, 12-13
 thoracic radiation therapy, 201
 tumor extension to, 6
- Mediastinoscopy, 43, 61, 89,
 127-128
- Medical oncology, 3, 16, 243-244
- Medical Outcomes Study Short
 Form Survey (SF-36), 222
- Medical Research Council
 Working Party study, 211
- Megace (megestrol acetate), 246
- Memorial Sloan-Kettering group,
 106
- Mesenchymal tumors, 60
- Mesotheliomas, 77
- Metabolism, radiographic
 evaluation, 40-42
- Metastatic disease
 adrenal, 27
 base-of-skull, 199
 bone, 225
 brain, 224
 central nervous system, 27-28
 extensive-stage SCLC, 209
 immunohistochemical staining,
 76-77
 laboratory studies, 29
 liver, 27
 locally advanced NSCLC and,
 120
 micrometastases, 112, 120
 NSCLC staging, 46-48
 occult micrometastases, 112
 patterns of spread, 6-7
 PET evaluation, 31
 primary tumors distinguished
 from, 76-77
 prophylactic cranial
 irradiation, 198-200
 signs and symptoms, 27-28
 SCLC, 21-22
 staging implications of, 36
 TNM definitions, 9
- Methyl methacrylate, 137, 226
- Microsatellite instability, 286
- MILES study, 162, 169
- Mitomycin, vinblastine, and
 cisplatin (MVP) therapy, 163
- Mitomycin C, 170
- MOC-31, 77
- Models of lung cancer
 development, 258-259,
 283-284
- Molecular biology techniques, 78
- Molecular events in lung cancer
 development, 280-298
- Molecular marker assays, 15
- Morphine, 245
- Morphology, diagnosis and, 38-40

- Mortality rates, 4, 95, 96, 119, 221
- Mucoepidermoid carcinomas, 76
- Multidisciplinary care
 chemotherapy in, 247-248
 complex tumors, 19
 implementation, 1-24
 NSCLC, 121
 pathway design, 89-97
 radiation therapy in, 247-248
 superior sulcus tumors, 226
 team approach, 16
- Multimodality therapy, 241-255, 253-254
- Multistep model of
 carcinogenesis, 259, 283-284
- MYC genes, 15, 273
- Myelitis, 17, 248
- Myelosuppression, 167
- Myocardial infarction, 143
- Narcotics, 245, 248
- National Cancer Institute (NCI), 191, 199-200, 269-270
- National Cancer Institute of
 Canada Clinical Trials
 Group, 194-195
- National Cancer Institute
 Surveillance, Epidemiology
 and End Results Program, 102
- National Comprehensive Cancer
 Network (NCCN), 86, 189,
 224-225
- National Health and Nutrition
 Examination Survey, 266
- Necrosis, tumor, 51
- Neovastat, 296
- Neu* oncogene, 15. *See also*
 HER-2/*neu* oncogene
- Neuroendocrine markers, 77
- Neuroendocrine tumors of the
 lung, 69-70
- Neurological symptoms, 14
- Neurotoxicity, 167, 199
- Neutropenia, 161
- Neutropenic fever, 201
- Neutrophil counts, 250
- Nickel, 6
- Nitrosamines, 259
- Nodular type II pneumocyte
 hyperplasia, 66
- Non-Pancoast tumors, 121,
 126-130, 138
- Non-Small Cell Lung Cancer
 Collaborative Group, 108-109
- Non-small cell lung cancer
 (NSCLC). *See entries for
 specific topics*
- Nonepithelial tumors, WHO
 classification, 65
- Nonmucinous bronchioalveolar
 adenocarcinoma (BAC),
 66-67
- Nuclear morphometry, 66
- Nutritional status, 201, 223-224,
 237-238
- Nutritional support, 246, 250
- Obstipation, 246
- Occlusive dressings, 245
- Odynophagia, 245
- Oncogenes, 15, 284. *See also entries
 for specific genes*
- ONYX-015, 272, 295
- Opacities, evaluation of, 38
- Operating room, clinical
 pathways, 93
- Opioids, 225, 246
- Organic chemicals, 6, 282
- OSI-774 (Tarceva), 179
- Osteolysis, 6
- Osteosarcomas, 39, 75
- Ototoxicity, 167
- Outcomes analysis, 94-96
- Outcomes documentation, 89
- Outpatient clinic visits, 91
- Oxycodone, 245
- Oxygen consumption testing, 32,
 122, 228

- p16* gene, 285
p19^{arf} gene, 285
p53 gene
 carcinogens and, 286
 cell growth and, 285
 defective, 294-295
 gene therapy, 271-273
 immunohistochemical staining,
 78
 mutations in atypical
 adenomatous hyperplasia, 66
 prognosis and, 291
 tumor growth and, 15
- Paclitaxel
 advanced NSCLC, 161
 best supportive care and, 165
 carboplatin and, 163
 cisplatin and, 168
 extensive-stage SCLC, 210, 216
 NSCLC, 18
 platinum-based regimens and,
 178
 preoperative, 109-110
 quality of life and, 164
- Pain management
 families, 225
 metastases and, 104
 oral medication, 111
 palliative care and, 222
 quality of life and, 224-225
 radiographic evaluation of, 31
 upper right quadrant, 27
- Palliative care, 220-224
 advanced NSCLC, 161
 alimentation and nutrition,
 237-238
 approaches, 223-237
 constitutional symptoms,
 223-224
 extensive-stage SCLC, 217
 radiographic evaluation, 31
 surgical, 20
 symptoms and, 223-237
- Pancoast tumors, 44, 121,
 129-130, 137-138
- Papillary growth, 66
 Papillomas, 63
 Para-aortic lymph nodes, 124, 125
 Paraneoplastic syndromes, 28-29,
 188, 209
 Partial pressure of oxygen, 143
 Pathology
 evaluation, 57-80
 molecular events, 280-298
 SCLC workup, 188
- Patient-controlled analgesia, 91
 Patient education
 clinical pathways, 89, 90, 91
 day of surgery, 92
 on discharge, 111
- Patient identifiers, 91
 Pedicled flaps, 253
 Performance status. *See also*
 entries for specific measurement
 tools
 advanced NSCLC survival
 and, 160
 extensive-stage SCLC, 209
 fitness for surgery, 143
 patient evaluation, 221-223
 SCLC outcomes and, 187
- Perfusion, 40-42, 105
 Pericardium, 6
 Phosphoinositide 3-kinase
 (PI3K), 284, 294
 Phrenic nerves, 6, 7
 Physical examination, 10-11,
 26-29, 103-105
 Physician orders, preprinted,
 84-85, 89
 Physician profiling, 96
 Physicians Health Study, 269
 Pituitary, anterior, 76-77
 Planning target volume (PTV),
 144-145
 Platinum-based regimens. *See*
 also entries for specific drugs
 EORTC 8975 study, 175
 GEPC 98-02 study, 175, 176
 neoadjuvant, 18

- NSCLC, 109, 159-160, 160-161
 - patient age and, 161
 - practice guidelines, 87-88
 - SCLC, 210
 - second-generation agents and, 170-173
 - TAX 317 study, 177
 - TAX 320 study, 177
 - third-generation agents and, 164-174, 170-173
- Pleomorphic carcinomas, 75
- Pleural catheters, chronic
 - indwelling, 20, 230-236
- Pleural effusion
 - at diagnosis, 7
 - diagnostic thoracentesis, 32
 - malignant, 228-234
 - NSCLC patients, 43, 45
 - practice guidelines, 87
 - recurrent, 228
 - SCLC and, 188
- Pleural flaps, 252
- Pleurodesis, 229
- Pleurx catheters, 230-236
- Pneumocytes, 76-77
- Pneumonia, 7, 27, 209
- Pneumonitis, 201, 246-247
- Pneumothorax, 42-43
- Polypeptide hormones, 209
- Positron emission tomography (PET)
 - coronal whole-body, 49-50
 - mediastinal lymph nodes, 12
 - NSCLC, 104
 - pretreatment evaluation, 15, 31, 112
 - SCLC, 188
 - screening, 277
- Postoperative evaluation, 62, 223
- Postoperative management, 110-111
- Posttreatment evaluation, 51-53
- Practice guidelines, 189, 224-225
- Precancerous lesions, 62-68, 261
- Preinvasive lesions, 62-68, 261
- Pretreatment evaluation
 - history, 10-11
 - for NSCLC, 103-105, 122-123, 143, 160, 164
 - palliative care, 221-223
 - pathology, 60-61
 - physical examination, 10-11
 - radiographic imaging, 29-31
 - for SCLC, 188-189, 208-209
 - staging, 8-15
 - thoracic surgery, 249-250
- Prevascular lymph nodes, 124, 125
- Prevention, 37
- Primary tumors
 - metastases distinguished from, 76-77
 - second, 269-270
- Prognosis, implications of
 - molecular changes for estimating, 291-292
- Prognostic factors for SCLC, 187-188, 209
- Prophylactic cranial irradiation (PCI), 135, 188, 198-200. *See also* Brain; Radiation therapy
- Prostaglandins, 265, 266
- Prostate cancer, 5
- Protein kinase C alpha, 179
- Pruritus, 245
- Pulmonary arteries, 237, 251
- Pulmonary arterioplasty, 227
- Pulmonary artery sleeve resection, 227
- Pulmonary blastomas, 75
- Pulmonary function testing, 32, 105, 228. *See also* entries for specific measures
- Pulmonary insufficiency, 227
- Pulmonary ligament lymph nodes, 124, 125
- Pulmonary lymph nodes, 6
- Pulmonary resection
 - artery sleeve, 227
 - clinical pathways, 89-97

- Pulmonary resection (*continued*)
 limited versus full, 106-107
 surgical strategy, 128-129
 thoracoscopic, 106
- Pulmonary reserves, 122-123
- Pulmonary tents, 251-252
- Pulmonary toxicity, 244
- Quality of life
 assessment tools, 222
 brain metastases, 224
 chemotherapy and, 163
 selection of agents and, 164
 surgical improvement, 19-20
- R115777, 273
- Radiation doses, maximum, 249
- Radiation therapy
 acute side effects, 245-248
 assessment of patients after, 36
 chemotherapy and. *See*
 Chemoradiation therapy
 complications, 17
 doses, maximum, 249
 external-beam, 225
 Horner's syndrome, 153
 hyperfractionated, 149, 150,
 195-197
 multidisciplinary treatment
 and, 244
 NSCLC, 17, 20, 105, 107-108
 for pain management, 225, 226
 postoperative, 138, 246-247
 practice guidelines, 89
 preoperative, 247
 prophylactic, 135, 188, 198-200
 RTOG 94-10, 151-152
 stage I NSCLC lesions, 142-146
 stage II NSCLC lesions, 147-148
 stage III NSCLC lesions,
 147-148
 suggested maximum doses, 249
 superior sulcus tumors,
 152-153
 surgery versus, 107-108
 target volumes, 144-145
 tissue integrity and, 251
- Radiation Therapy Oncology
 Group (RTOG), 198
 83-11 trial, 147
 88-08 trial, 148, 149
 91-06 trial, 149
 92-04 trial, 149-151
 93-09 trial, 131-132
 93-11 trial, 145
 94-10 trial, 151-152, 244
 Intergroup study 0096, 196
 SCLC and, 191
- Radiographic imaging. *See also*
entries for specific technologies
 adrenal metastases, 27
 assessment after treatment, 36
 chest, 11, 29
 diagnostic, 7, 29-31
 estimation of growth, 39-40
 evaluation of response to
 treatment, 51
 future trends, 97-99
 NSCLC, 104
 pretreatment evaluation, 11-12
 SCLC, 188
- Radiopharmaceuticals, 225
- Radon, 6, 282
- Raf genes, 284
- RAS genes, 273-274
- Ras mutations, 292-294
- RASSF1A genes, 285
- Reactive alveolar epithelial
 hyperplasia, 66
- Reactive hyperplasia, 30
- Readmission rates, 95
- Recovery rooms, 93
- Recurrent disease
 limited resection and, 106-107
 NSCLC, 52
 SCLC, 215-217
 T1-3N2 tumors, 132, 133
- Recurrent nerves, 6
- Reducing Tobacco Use: A Report of*
the Surgeon General, 259

- Refractory SCLC, 215-217
- Renal toxicity, 167, 253
- Resections. *See* Surgical resection
- Respiratory findings, 104
- Respiratory insufficiency, 227
- Response to treatment, 51-53
- Retinoblastoma (*RB*) gene, 15, 78, 285
- 13-*cis* Retinoic acid (13-*cRA*), 262
- Retinoic acid receptor- β (*RAR*- β), 270-271
- Retinoic X receptor- β , 270
- Retinoids, 262
- Retinyl palmitate, 263-264, 268, 269
- Retrotracheal lymph nodes, 124, 125
- Rhabdomyosarcoma, 75
- RhoB, 293
- Risk estimation, 288-289

- S66336, 293
- Salivary-gland-type carcinomas, 64, 76
- Sarcomatoid carcinomas, 75, 78
- Scarring, 51
- SCH66336, 273
- Sclerotherapy, 229-230
- Screening
 - cardiovascular, 122
 - difficulties, 3, 7
 - interest in, 37-38
 - lung cancer, 275-277
 - molecular changes, 290
 - pretreatment PET, 112
 - smoking history, 112-113
 - survival rates and, 35-36
- Segmental lymph nodes, 124, 126
- Seizures, 224
- Selenium, 264-265, 270
- Senna, 246
- Seromas, 254
- Serum chemistry, 29
- SF-36 (Medical Outcomes Study Short Form Survey), 222

- Signaling pathways, 292-294
- Signs and symptoms of lung cancer, 26-27, 209-210
- Skin reactions, 245
- Small cell lung cancer (SCLC). *See* *entries for specific types*
- Smoking
 - assessment of, 223
 - cessation, 260, 282
 - exposure to, 6, 282
 - lung cancer and, 257-258, 259
 - neuroendocrine tumors and, 70
 - prevention interventions, 260
 - respiratory insufficiency, 227
 - SCLC outcomes and, 188
 - SCLC risk and, 208
 - screening based on, 112-113
- Social habits, assessment, 223
- Sodium levels, 188, 209. *See also* Electrolyte abnormalities
- Sonography, transesophageal, 14
- Southwest Oncology Group, 191
- Spinal column reconstruction, 226
- Spinal cord
 - compression, 28
 - invasion of, 137-138
 - metastases, 199
 - myelitis, 17
 - suggested maximum radiation doses, 249
 - surgical resection, 19
- Spinal fixation, 137-138
- Spinal instrumentation, 226
- Spirometry, 87, 105, 122
- Sputum, 7, 14, 32
- Squamous cell carcinomas
 - frequency, 69
 - NSCLC classification as, 60
 - outcomes, 227
 - p53* mutations, 78
 - pathology, 69
 - TTF-1 staining, 76-77
 - WHO classification, 63
- Squamous dysplasia, 62, 63, 64-65, 78

- Squamous metaplasia, 263-264
- Staffing models, 94
- Staging
 downstaging by chemotherapy, 136
 groupings for, 11
 measurement bias, 111-113
 nonsurgical treatment and, 143-152
 NSCLC, 17-19, 36, 43-48, 123-130
 pretreatment evaluation, 8-15
 regional lymph node stations, 124
 SCLC, 48-51, 208-209
 therapeutic choices and, 8
- Staples, 251, 252
- Stents, 235-236, 237
- Stridor, 7, 27
- Subaortic lymph nodes, 124, 125
- Subcarinal lymph nodes, 124, 125
- Subclavian arteries, 137
- Submucosal tumors, 33
- Subsegmental lymph nodes, 124, 126
- Sucralfate (Carofate) slurries, 245
- Superior sulcus tumors, 86-87, 152-153, 225-227
- Superior vena cava syndrome, 7, 27, 209
- Superior vena cavae, 6
- Surfactant apoprotein A, 76
- Surgeon General, 259
- Surgeons, team work, 3, 16
- Surgery. *See also* Surgical resection
 brain metastases, 19, 224
 fitness for, 143
 future trends, 97-99
 NSCLC, 17-18, 19-20, 105-107, 118-141
 radiation therapy versus, 107-108
 SCLC, 88-89
- Surgical resection. *See also* Surgery
 assessment of patients after, 36
 brain metastases, 19, 224
 bronchial sleeve, 227
 bronchoscopy prior to, 13
 chest wall, 128
 chest wall, en bloc, 226
 clinical pathways, 89-97
 limited versus full, 106-107
 pulmonary artery sleeve resection, 227
 spinal cord, 19
 strategy, 128-129
 thoracoscopic, 106
 tracheal, 227
- Survival rates
 improvement, 3
 NSCLC, 8
 palliative care and, 221
 SCLC, 209
 screening and, 35-36
 surgical improvement, 19
- Swallowing, 246
- Swelling, 26
- Synaptophysin, 71, 72, 77
- Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 29, 209
- Talc sclerotherapy, 229
- Tarceva (OSI-774), 179
- Targeted receptor therapy, 21
- Targretin (LGD1069), 293
- TAX 317 study, 177
- TAX 320 study, 177
- TAX 326 study, 167, 169, 173
- Taxanes, 210
- Taxotere. *See* Docetaxel
- Telemetry units, 93
- Telomerase activity, 66
- Telomerase genes, 287
- Teniposide, 210

- Thalidomide, 296
- Thoracentesis, 32, 188, 229
- Thoracic radiation therapy (TRT)
 CNS metastases and, 200
 dose to thorax, 197-198
 fractionation, 195-197
 at M. D. Anderson, 200-201
 SCLC, 187, 189-201
 volume irradiated, 195
- Thoracic surgery, sequelae, 248-254
- Thoracoscopy, video-assisted, 13
- Thoracotomy
 emergency, 237
 posterior-lateral, 226
- Thoracotomy trays, 93
- Thromboxanes, 265
- Thrush, 245
- Thyroid gland, 76-77
- Thyroid transcription factor 1
 (TTF-1), 76-77
- Tirapazamine, 167, 168
- TisSeel, 252
- Tissue margins, 61
- Tissue sealants, 252
- T4N0-1 tumors, 135-138
- T3N1 tumors, 123, 126-130
- TNP-470, 296
- Tobacco. *See* Smoking
- α -Tocopherol, 264, 268
- Topoisomerase I inhibitors, 210
- Topotecan, 210, 216
- Tracheal resection, 227
- Transbronchial biopsies, 13, 33, 60
- Transesophageal sonography, 14
- Transforming growth factor
 alpha, 287
- Transfusions, 250
- Transthoracic needle aspiration
 (TTNA) biopsy, 13-14, 34,
 42-43
- "Trapped" lung, 230
- Trastuzumab (Herceptin), 178
- Tube thoracostomy, 229
- Tumor burden, 223
- Tumor growth, diagnosis and,
 38-40, 59
- Tumor suppressor genes,
 284-286. *See also* entries for
specific genes
- Tumor volume, 40
- Unclassified carcinomas, 64, 76
- Union Internationale Contre le
 Cancer, 8
- Upper airway obstruction, 27
- Upper paratracheal lymph nodes,
 124, 125
- Vascular endothelial growth factor
 (VEGF), 178-179, 179, 287
- Vascular endothelial growth
 factor receptor (VEGFR), 296
- Venous distension, 26-27
- Vertebral bodies, 31
- Vertebral invasion, 226
- Vertebrectomy, 226
- Veterans Administration Lung
 Cancer Study Group trial, 48,
 210
- Video-assisted thoracic surgery
 (VATS), 229
- Video-assisted thoracoscopy, 13
- Vinblastine, 148, 150, 151-152, 163
- Vinca alkaloids, 210. *See also*
entries for specific agents
- Vincristine, 191, 194, 195, 210
- Vindesine, 21, 166, 170
- Vinorelbine
 best supportive care and, 162,
 165
 cisplatin and, 166, 167, 168
 ifosfamide and, 177-178
 MVP therapy and, 163
 NSCLC, 161
 platinum-based agents with,
 170
 quality of life and, 164
 SCLC, 210

- Vitamin A, 262
- Vocal cord paralysis, 27
- Vocal cords, 93

- Weakness, 29
- Weight loss. *See also* Anorexia;
 Appetite; Cachexia
 at diagnosis, 7
 palliative care and, 222
 paraneoplastic disorders and,
 28
 during radiation therapy, 246
 SCLC, 209
- Wheezing, 7

- White blood cell count, 250
- World Health Organization
 (WHO) classification, 62,
 63-64, 65
- Wound care, 91, 111, 254
- Wound dehiscence, 246
- WR21-27 (ethyol), 21

- Xenon ventilation perfusion lung
 scanning, 32, 228

- ZD1839 (Iressa), 179, 274-275, 296
- Zubrod performance status, 222,
 233-234, 247